Vivolution Acquires Extensive Patent Portfolio from Bristol-Meyers Squibb

ConvaTec, a subsidiary of Bristol-Meyer Squibb, who developed the VivostatSystem, and subsequently sold the project to Vivolution A/S, has agreed to sell all patents covering the Vivostat technology and other related technologies for an undisclosed sum.

The patent portfolio covers 66 issued and 20 pending patents, covering a large number of countries. The acquisition by Vivolution marks the end of a long relationship with ConvaTec and provides Vivolution with the option to out-license the technology to strategic partners.

"I am very happy that we have finalized the acquisition after three years of negotiation", says Tom Bjerg Lauritzen, CEO of Vivolution A/S. "We are now completely independent and can now develop our own patent strategy."

For further information please contact:

Tom Bjerg Lauritzen

CEO

Tel. +45 8880 8420

Email: tbl@vivolution.com

Or visit www.vivolution.com

Home > News & Events > News > Vivolution Acquires Extensive Patent Portfolio from Bristol-Meyers Squibb
Last updated: 2008-02-29

The official Medicon Valley site is brought to you by the organisations Region Skåne and Copenhagen Capacity - in association with Medicon Valley Alliance

Contact:
Copenhagen Capacity,	tel: +45 33 22 02 22
Region Skåne,	tel: +46 (0)40 623 97 48

VIVOSTAT A/S

VIVOSTAT A/S

Vivostat A/S develops and manufactures medical devices that improve the quality of surgical and wound care procedures. The company works closely with surgeons and wound care specialists in many countries to ensure that the products remain state-of-the-art.